Transthyretin Amyloidosis Treatment Market
Report ID: SQMIG35H2504
Report ID: SQMIG35H2504
[email protected]
USA +1 351-333-4748
Report ID:
SQMIG35H2504 |
Region:
Global |
Published Date: May, 2026
Pages:
157
|Tables:
174
|Figures:
79
Global Transthyretin Amyloidosis Treatment Market size was valued at USD 7.2 Billion in 2024 and is poised to grow from USD 8.2 Billion in 2025 to USD 23.23 Billion by 2033, growing at a CAGR of 13.9% during the forecast period (2026-2033).
The primary driver of the transthyretin amyloidosis treatment market is the emergence of effective disease-modifying therapies that have transformed a previously symptomatic and palliative care landscape into one focused on altering disease trajectory. Transthyretin amyloidosis treatments target either protein stabilization, RNA silencing, or replacement approaches, and this market matters because affected patients face progressive cardiac and neurologic decline with high morbidity and mortality. Over the last decade diagnostic advances such as noninvasive cardiac scintigraphy and expanded genetic testing increased case identification, while regulatory approvals for example tafamidis for cardiomyopathy and patisiran for polyneuropathy catalyzed investment and commercial development.A pivotal factor shaping global market expansion is the widening diagnostic ecosystem, because more reliable detection and proven clinical benefit create a virtuous cycle of adoption and investment. As noninvasive imaging and genetic screening uncover unrecognized patients, pharmaceutical companies accelerate trials and broaden indications, which in turn persuades payers to reimburse high-cost agents after real-world evidence shows reduced hospitalizations and slowed functional decline; for example tafamidis has demonstrated lower mortality in ATTR cardiomyopathy while patisiran and inotersen improved neuropathy scores. This cascade creates opportunities for gene therapies, diagnostic-commercial partnerships, and market penetration in underserved regions as stakeholders align incentives strategically.
How is AI accelerating drug discovery and patient stratification in the transthyretin amyloidosis treatment market?
AI is accelerating drug discovery and patient stratification in transthyretin amyloidosis through complementary capabilities. In discovery AI improves target interrogation and suggests optimized small molecules and biologics by modeling protein pockets and binding scenarios. In clinical stratification AI analyzes imaging and electronic health record patterns to flag likely cardiac or neuropathic presentations and to refine biomarker driven cohorts. The market is evolving beyond broad stabilizers toward targeted RNA therapies and amyloid depleters. Smarter preclinical screening and AI guided enrollment reduce wasted effort and make trials more efficient. Examples include new protein design engines and prospective AI enabled echocardiography models that improve case finding.Alnylam Pharmaceuticals March 2026, announced a partnership with Viz.ai to deploy AI based echocardiography workflows and electronic health record connectivity to speed diagnosis and care coordination. This move helps find eligible patients earlier and channels higher quality candidates into trials and targeted therapies which supports faster market uptake and clinical efficiency.
Market snapshot - (2026-2033)
Global Market Size
USD 7.2 Billion
Largest Segment
Transthyretin Stabilizers
Fastest Growth
Gene Silencing Therapies
Growth Rate
13.9% CAGR
To get more insights on this market click here to Request a Free Sample Report
Global transthyretin amyloidosis treatment market is segmented by drug type, disease type, application, route of administration, distribution channel, end user and region. Based on drug type, the market is segmented into Transthyretin Stabilizers, Gene Silencing Therapies, Monoclonal Antibodies, Supportive Therapies and Others. Based on disease type, the market is segmented into Hereditary ATTR Amyloidosis and Wild-Type ATTR Amyloidosis. Based on application, the market is segmented into Polyneuropathy, Cardiomyopathy and Mixed Manifestations. Based on route of administration, the market is segmented into Oral, Intravenous and Subcutaneous. Based on distribution channel, the market is segmented into Hospital Pharmacies, Retail Pharmacies, Specialty Pharmacies and Online Pharmacies. Based on end user, the market is segmented into Hospitals, Specialty Clinics, Ambulatory Care Centers and Homecare Settings. Based on region, the market is segmented into North America, Europe, Asia Pacific, Latin America and Middle East & Africa.
What role do transthyretin stabilizers play in advancing the transthyretin amyloidosis treatment market? |@12
Transthyretin Stabilizers segment dominates because their mechanism directly addresses misfolded TTR tetramer stabilization, offering clinicians a clear, disease-modifying option with familiar pharmacology and predictable safety. Strong clinical validation and regulatory acceptance have increased prescriber confidence and eased payer pathways, which in turn supports earlier diagnosis and routine therapy initiation. Lower logistical complexity relative to advanced biologics further reduces adoption barriers, widening clinical uptake across neuropathic and cardiac patients.
However, Gene Silencing Therapies are emerging as the most rapidly expanding sub-segment in the Transthyretin Amyloidosis Treatment Market, driven by RNA technologies that markedly lower TTR production and show deep disease modification. Rapid innovation, robust pipeline activity, and favorable regulatory momentum are accelerating adoption and creating new therapeutic and commercial opportunities centered on durable dosing and combination approaches.
How is oral administration influencing treatment adoption in the transthyretin amyloidosis treatment market? |@12
Oral segment dominates because oral therapies align with patient preferences for convenience and support long-term adherence in chronic transthyretin amyloidosis management, enabling outpatient initiation and follow-up. Simpler administration reduces clinic burden and streamlines supply and reimbursement processes, encouraging prescribers to favor accessible options. This accessibility promotes earlier treatment starts and sustained therapy, reinforcing oral approaches as a primary option across neuropathic and cardiac manifestations.
However, Subcutaneous administration is witnessing the strongest growth momentum as novel formulations enable at-home dosing with improved tolerability and convenient intervals. The emergence of subcutaneous biologics and long-acting platforms reduces reliance on infusion centers, supports decentralization of care, and appeals to patients and payers. This trend enhances access and adherence while unlocking new care delivery models that expand market opportunities.
To get detailed segments analysis, Request a Free Sample Report
Why does North America Dominate the Global Transthyretin Amyloidosis Treatment Market? |@12
North America commands the global transthyretin amyloidosis treatment market due to a confluence of medical, regulatory, and commercial strengths. The region benefits from advanced diagnostic networks and highly specialized clinical care pathways that enable early detection and multidisciplinary management. A concentrated presence of biotechnology and pharmaceutical innovators accelerates therapeutic development and commercialization. Well established reimbursement frameworks and engaged payer communities foster market access for novel therapies, while active patient advocacy and professional societies drive awareness and guideline adoption. Research ecosystems and experienced contract research organizations support translational work and trial execution across diverse clinical settings. Together, these capabilities create a responsive environment where new treatment modalities are adopted and scaled, reinforcing North America position as a dominant market hub and a launchpad for global therapeutic strategies.
United States Transthyretin Amyloidosis Treatment Market |@12
Transthyretin Amyloidosis Treatment Market in United States is characterized by concentrated research and commercial activity led by biotechnology and pharmaceutical innovators, tertiary care networks, and specialty centers that facilitate multidisciplinary management and uptake of advanced therapies. Robust diagnostic pathways and active clinical trial infrastructure support identification and treatment of patients, while payer and reimbursement mechanisms enable commercialization. Strong patient advocacy and professional society engagement reinforce clinician awareness and guideline integration.
Canada Transthyretin Amyloidosis Treatment Market |@12
Transthyretin Amyloidosis Treatment Market in Canada is shaped by a publicly funded healthcare environment with provincial decision making and specialty care networks that support diagnosis and management. Academic centers and collaborative research initiatives support therapeutic evaluation and clinician education. Centralized procurement and formulary processes influence access and uptake of novel treatments, while patient advocacy groups and networks work to enhance awareness, testing pathways, and integration of multidisciplinary care across systems.
What is Driving the Rapid Expansion of Transthyretin Amyloidosis Treatment Market in Europe? |@12
Europe is experiencing rapid expansion in the transthyretin amyloidosis treatment market as a result of converging clinical, regulatory, and commercial dynamics. Enhanced clinician awareness and the maturation of specialist referral networks have improved case identification and management across multiple healthcare systems. Pan regional research collaborations and investigator led trials are accelerating evidence generation, while evolving reimbursement frameworks and national assessment pathways are creating clearer routes for market entry. Strong engagement from patient organizations and professional societies is promoting guideline development and testing initiatives. Additionally, consolidated industry presence and strategic partnerships with clinical centers support localized launch planning and real world evidence collection, enabling faster adoption of new therapeutic options across diverse European markets. Investment in diagnostic capacity and professional training is enhancing detection and referral consistency. Dialogue between manufacturers and health technology assessment bodies is also becoming more structured, reducing barriers to reimbursement and supporting phased access across markets.
Germany Transthyretin Amyloidosis Treatment Market |@12
Transthyretin Amyloidosis Treatment Market in Germany is anchored by comprehensive specialty networks, expert cardiology and neurology centers, and a clinical research environment that supports therapeutic evaluation and adoption. Structured assessment and reimbursement pathways facilitate market access for novel therapies, while strong diagnostic capacity and referral systems aid timely patient identification. Close collaboration between academic centers, industry, and patient organizations promotes guideline development and real world evidence generation across care hubs.
United Kingdom Transthyretin Amyloidosis Treatment Market |@12
Transthyretin Amyloidosis Treatment Market in United Kingdom is driven by national healthcare structures, specialist centers, and adoption pathways that enable therapy integration. Strengthened diagnostic services and clinician expertise support timely referral and multidisciplinary care. Policy dialogues and structured reimbursement processes are aligning to facilitate access, while active patient communities and academic networks contribute to awareness and evidence generation with clinician training programs. These factors underpin market momentum across care settings.
France Transthyretin Amyloidosis Treatment Market |@12
Transthyretin Amyloidosis Treatment Market in France is emerging through strengthened clinical networks, centralized evaluation pathways, and expanding diagnostic capability in cardiology centers. Research groups and specialty clinics collaborate with industry to build evidence and clinician education. National health assessment processes and access initiatives shape adoption, while patient associations and regional centers promote screening and referral. These combined elements support progressive integration of advanced therapeutic options into national standard care pathways.
How is Asia Pacific Strengthening its Position in Transthyretin Amyloidosis Treatment Market? |@12
Asia Pacific is strengthening its role in the transthyretin amyloidosis treatment market through coordinated investments in clinical capacity, diagnostics, and local research partnerships. Key markets are building specialized centers of excellence that integrate cardiology and neurology expertise and that support multidisciplinary care pathways. Increasing collaboration between regional academic institutions and international sponsors is expanding clinical trial presence and evidence generation. Regulatory agencies are evolving pathways to accommodate innovative therapies, while local manufacturing and supply chain initiatives are improving market readiness. Enhanced awareness campaigns led by patient groups and professional societies are improving detection and referral, and digital health platforms are extending specialist access into broader population centers, collectively advancing regional market maturation and attractiveness for global and local stakeholders. Public private initiatives and knowledge transfer programs are also contributing to capacity building and clinician training across the region.
Japan Transthyretin Amyloidosis Treatment Market |@12
Transthyretin Amyloidosis Treatment Market in Japan benefits from advanced clinical infrastructure, robust diagnostic laboratories, and specialty centers that support integrated cardiology and neurology care. A progressive regulatory environment and active engagement between industry and academic institutions facilitate clinical evaluation and evidence generation. National reimbursement pathways and hospital adoption decisions influence access, while strong clinician networks and patient advocacy promote testing, referral, and incorporation of novel therapeutic approaches into clinical practice.
South Korea Transthyretin Amyloidosis Treatment Market |@12
Transthyretin Amyloidosis Treatment Market in South Korea is characterized by an advanced healthcare delivery system, developed diagnostic services, and specialty clinics that facilitate multidisciplinary management. Collaboration between research institutions and international sponsors enhances clinical trial activity and evidence generation. Health policy frameworks and centralized reimbursement decision making shape access, while patient advocacy and professional societies increase awareness, drive screening initiatives, and support clinician education to expand adoption of new therapies.
To know more about the market opportunities by region and country, click here to
Buy The Complete Report
Drivers |@12
Advances In Therapeutic Development
Rising Disease Awareness and Diagnosis
Restraints |@12
High Treatment Cost and Access
Limited Long Term Real World Evidence
Request Free Customization of this report to help us to meet your business objectives.
The competitive landscape for the global transthyretin amyloidosis treatment market is driven by targeted M&A, large pharma acquisitions, and platform innovation that change incumbentsโ R&D priorities. Notable moves include Novo Nordiskโs acquisition of Prothenaโs ATTR program, the Regeneron and Intellia co-development of an in vivo CRISPR ATTR candidate, and BridgeBioโs recent regulatory milestone that intensified commercial competition and technology investment.
Top Playerโs Company Profile
Recent Developments
SkyQuestโs ABIRAW (Advanced Business Intelligence, Research & Analysis Wing) is our Business Information Services team that Collects, Collates, Correlates, and Analyses the Data collected by means of Primary Exploratory Research backed by robust Secondary Desk research. As per SkyQuest analysis, the transthyretin amyloidosis treatment market is propelled by the emergence of effective disease-modifying therapies as one key driver, while high treatment cost and limited reimbursement remain a major restraint. North America is the dominating region given its advanced diagnostic networks and commercial infrastructure, and transthyretin stabilizers are the dominating segment due to established clinical evidence, predictable safety and logistical simplicity. A second driver is expanding diagnostic capacity and AI-enabled patient stratification that increase case finding, accelerate trial enrollment, and support broader adoption across cardiology and neurology care pathways and encourage partnerships between diagnostics firms, payers and manufacturers to build real world evidence and improve access.
| Report Metric | Details |
|---|---|
| Market size value in 2024 | USD 7.2 Billion |
| Market size value in 2033 | USD 23.23 Billion |
| Growth Rate | 13.9% |
| Base year | 2024 |
| Forecast period | (2026-2033) |
| Forecast Unit (Value) | USD Billion |
| Segments covered |
|
| Regions covered | North America (US, Canada), Europe (Germany, France, United Kingdom, Italy, Spain, Rest of Europe), Asia Pacific (China, India, Japan, Rest of Asia-Pacific), Latin America (Brazil, Rest of Latin America), Middle East & Africa (South Africa, GCC Countries, Rest of MEA) |
| Companies covered |
|
| Customization scope | Free report customization with purchase. Customization includes:-
|
To get a free trial access to our platform which is a one stop solution for all your data requirements for quicker decision making. This platform allows you to compare markets, competitors who are prominent in the market, and mega trends that are influencing the dynamics in the market. Also, get access to detailed SkyQuest exclusive matrix.
Table Of Content
Executive Summary
Market overview
Parent Market Analysis
Market overview
Market size
KEY MARKET INSIGHTS
COVID IMPACT
MARKET DYNAMICS & OUTLOOK
Market Size by Region
KEY COMPANY PROFILES
Methodology
For the Transthyretin Amyloidosis Treatment Market, our research methodology involved a mixture of primary and secondary data sources. Key steps involved in the research process are listed below:
1. Information Procurement: This stage involved the procurement of Market data or related information via primary and secondary sources. The various secondary sources used included various company websites, annual reports, trade databases, and paid databases such as Hoover's, Bloomberg Business, Factiva, and Avention. Our team did 45 primary interactions Globally which included several stakeholders such as manufacturers, customers, key opinion leaders, etc. Overall, information procurement was one of the most extensive stages in our research process.
2. Information Analysis: This step involved triangulation of data through bottom-up and top-down approaches to estimate and validate the total size and future estimate of the Transthyretin Amyloidosis Treatment Market.
3. Report Formulation: The final step entailed the placement of data points in appropriate Market spaces in an attempt to deduce viable conclusions.
4. Validation & Publishing: Validation is the most important step in the process. Validation & re-validation via an intricately designed process helped us finalize data points to be used for final calculations. The final Market estimates and forecasts were then aligned and sent to our panel of industry experts for validation of data. Once the validation was done the report was sent to our Quality Assurance team to ensure adherence to style guides, consistency & design.
Analyst Support
Customization Options
With the given market data, our dedicated team of analysts can offer you the following customization options are available for the Transthyretin Amyloidosis Treatment Market:
Product Analysis: Product matrix, which offers a detailed comparison of the product portfolio of companies.
Regional Analysis: Further analysis of the Transthyretin Amyloidosis Treatment Market for additional countries.
Competitive Analysis: Detailed analysis and profiling of additional Market players & comparative analysis of competitive products.
Go to Market Strategy: Find the high-growth channels to invest your marketing efforts and increase your customer base.
Innovation Mapping: Identify racial solutions and innovation, connected to deep ecosystems of innovators, start-ups, academics, and strategic partners.
Category Intelligence: Customized intelligence that is relevant to their supply Markets will enable them to make smarter sourcing decisions and improve their category management.
Public Company Transcript Analysis: To improve the investment performance by generating new alpha and making better-informed decisions.
Social Media Listening: To analyze the conversations and trends happening not just around your brand, but around your industry as a whole, and use those insights to make better Marketing decisions.
REQUEST FOR SAMPLE
REQUEST FREE CUSTOMIZATION
Want to customize this report? This report can be personalized according to your needs. Our analysts and industry experts will work directly with you to understand your requirements and provide you with customized data in a short amount of time. We offer $1000 worth of FREE customization at the time of purchase.
Feedback From Our Clients
USA (+1) 351-333-4748
